231
Diasorin closed the first quarter with strong growth results (still supported by test sales for Coronavirus but also supported by the recovery of ex-Covid revenues) and looks confidently at visibility for the rest of the year, releasing a guidance that foresees double-digit growth, with a wide range (15-25%) linked to the uncertainties on the effects of the vaccination plan and on the evolution of the pandemic situation.
In the first part of the year the group recorded a net profit …